In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS unmoved by rival bid for ImClone Systems

This article was originally published in Scrip

Executive Summary

Bristol-Myers Squibbwill stand by its $4.4 billion bid forImClone Systems, a day after the offer was rebuffed and a mystery suitor emerged with a competing proposal. BMS also reiterated its claim to the Erbitux (cetuximab) follow-on IMC-11F8, which is a contentious issue for the firms.

Advertisement
Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel